Markets
Aberdeen Angus Bull
Aberdeen Angus bull (Getty Images)

Two tech titans singlehandedly drag S&P 500 higher

Alphabet and Apple put the stock market on their broad, multitrillion-dollar shoulders.

Nia Warfield, Luke Kawa
9/3/25 3:58PM

The S&P 500 rose 0.5% and the Nasdaq 100 gained 0.8% while the Russell 2000 dipped 0.1% on Wednesday.

More than all of the daily returns in the SPDR S&P 500 ETF were attributable to just two companies: Alphabet and Apple.

Google was the day’s top performer, up 9.1% after the tech giant avoided some of the worst-case antitrust scenarios tied to its dominant position in search. The court decision helped Apple a ton, too: shares rose 3.8% after Bank of America boosted its price target, saying the company will keep pulling in about $20 billion a year from Google to preload its apps as the default setting on iPhones. Near the close, Bloomberg reported that Apple is developing an AI web search tool for the new Siri and reached an agreement with Google to test using its Gemini model to provide the underlying technology. Meanwhile, Dollar Tree led declines after the retailer handily beat Q2 expectations, but fresh sales guidance suggested weakening momentum in the second half of the year.

Macy’s shares soared 20.6% after the department store chain posted knockout Q2 results and raised its full-year guidance.

Hims & Hers spiked 7.2% after a judge dismissed a lawsuit from Eli Lilly against another rival telehealth firm selling knockoff versions of its GLP-1 drugs.

Campbell’s stock climbed 7.2% after the soup maker ladled out solid Q4 results as more cash-strapped consumers cooked at home, but warned that higher costs would weigh on margins.

Plug Power jumped in the premarket amid a surge of trading volume in the hydrogen fuel cell company before closing up 1.4%.

Oscar Health rose after it reiterated its annual guidance and offered positive commentary on cost trends at the Wells Fargo Healthcare Conference.

Oil names including ConocoPhillips, Phillips 66, APA Corporation, Diamondback Energy, Devon Energy, Halliburton, and EOG Resources all dipped after reports that OPEC+ is weighing another output hike of 1.65 million barrels per day.

Canopy Growth shares fell another 6.7%, extending Tuesday’s losses after the cannabis company filed for a $200 million equity raise on Friday.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.